+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Kadcyla"

UAE Breast Cancer Drugs Market, By Region, Competition, Forecast and Opportunities, 2020-2030F - Product Thumbnail Image

UAE Breast Cancer Drugs Market, By Region, Competition, Forecast and Opportunities, 2020-2030F

  • Report
  • January 2025
  • 82 Pages
  • United Arab Emirates United Arab Emirates
From
Antibody Drug Conjugates Market - Forecasts from 2024 to 2029 - Product Thumbnail Image

Antibody Drug Conjugates Market - Forecasts from 2024 to 2029

  • Report
  • February 2024
  • 210 Pages
  • Global
From
From
From
From
From
From
Antibody Drug Conjugates Market Report and Forecast 2024-2032 - Product Thumbnail Image

Antibody Drug Conjugates Market Report and Forecast 2024-2032

  • Report
  • September 2023
  • 140 Pages
  • Global
From
From
From
Antibody-Drug Conjugates (ADC): Market Overview - Product Thumbnail Image

Antibody-Drug Conjugates (ADC): Market Overview

  • Report
  • March 2024
  • 86 Pages
  • Global
From
From
Global Cancer Immunotherapy Market Analysis & Forecast to 2025 - Product Thumbnail Image

Global Cancer Immunotherapy Market Analysis & Forecast to 2025

  • Report
  • November 2020
  • 450 Pages
  • Global
From
Drug Delivery in Cancer - Technologies, Markets & Companies - Product Thumbnail Image

Drug Delivery in Cancer - Technologies, Markets & Companies

  • Report
  • November 2021
  • 747 Pages
  • Global
From
Loading Indicator

Kadcyla is an oncology drug used to treat certain types of breast cancer. It is a targeted therapy that works by blocking the HER2 protein, which is found in some types of breast cancer cells. Kadcyla is administered intravenously and is used in combination with other treatments such as chemotherapy and radiation. It is approved for use in the United States, Europe, and other countries. Kadcyla is a relatively new drug and is still in the early stages of development. It is being studied in clinical trials for its potential to treat other types of cancer, such as ovarian and lung cancer. The drug is also being studied for its potential to reduce the risk of recurrence in patients who have already been treated for breast cancer. The Kadcyla market is highly competitive, with several major pharmaceutical companies competing for market share. Companies such as Roche, Novartis, and Pfizer are all involved in the development and marketing of Kadcyla. Other companies such as Merck, AstraZeneca, and Eli Lilly are also involved in the development and marketing of the drug. Show Less Read more